Abstract
The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.
RAS ID
27178
Document Type
Journal Article
Date of Publication
2018
School
School of Medical and Health Sciences
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Publisher
Elsevier
Recommended Citation
Marsavela, G., Aya-Bonilla, C. A., Warkiani, m. E., Gray, E. S., & Ziman, M. R. (2018). Melanoma circulating tumor cells: Benefits and challenges required for clinical application. DOI: https://doi.org/10.1016/j.canlet.2018.03.013
Comments
Marsavela, G., Aya-Bonilla, C. A., Warkiani, M. E., Gray, E. S., & Ziman, M. (2018). Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer letters. Available here